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Association of Mild to Moderate Chronic Kidney Disease
With Venous Thromboembolism
Pooled Analysis of Five Prospective General Population Cohorts
Bakhtawar K. Mahmoodi, MD, PhD; Ron T. Gansevoort, MD, PhD; Inger Anne Næss, MD, PhD;
Pamela L. Lutsey, PhD, MPH; Sigrid K. Brækkan, PhD; Nic J.G.M. Veeger, PhD;
Ellen E. Brodin, MD, PhD; Karina Meijer, MD, PhD; Yingying Sang, MSc;
Kunihiro Matsushita, MD, PhD; Stein I. Hallan, MD, PhD; Jens Hammerstrøm, MD, PhD;
Suzanne C. Cannegieter, MD, PhD; Brad C. Astor, PhD, MPH; Josef Coresh, MD, PhD;
Aaron R. Folsom, MD, MPH; John-Bjarne Hansen, MD, PhD; Mary Cushman, MD, MSc
Background—Recent findings suggest that chronic kidney disease (CKD) may be associated with an increased risk of
venous thromboembolism (VTE). Given the high prevalence of mild-to-moderate CKD in the general population, in
depth analysis of this association is warranted.
Methods and Results—We pooled individual participant data from 5 community-based cohorts from Europe (second
Nord-Trøndelag Health Study [HUNT2], Prevention of Renal and Vascular End-stage Disease [PREVEND], and the Tromsø
study) and the United States (Atherosclerosis Risks in Communities [ARIC] and Cardiovascular Health Study [CHS]) to
assess the association of estimated glomerular filtration rate (eGFR), albuminuria, and CKD with objectively verified VTE.
To estimate adjusted hazard ratios for VTE, categorical and continuous spline models were fit by using Cox regression with
shared-frailty or random-effect meta-analysis. A total of 1178 VTE events occurred over 599 453 person-years follow-up.
Relative to eGFR 100 mL/min per 1.73 m2, hazard ratios for VTE were 1.29 (95% confidence interval, 1.04–1.59) for eGFR
75, 1.31 (1.00–1.71) for eGFR 60, 1.82 (1.27–2.60) for eGFR 45, and 1.95 (1.26–3.01) for eGFR 30 mL/min per 1.73 m2.
In comparison with an albumin-to-creatinine ratio (ACR) of 5.0 mg/g, the hazard ratios for VTE were 1.34 (1.04–1.72) for
ACR 30 mg/g, 1.60 (1.08–2.36) for ACR 300 mg/g, and 1.92 (1.19–3.09) for ACR 1000 mg/g. There was no interaction
between clinical categories of eGFR and ACR (P0.20). The adjusted hazard ratio for CKD, defined as eGFR60 mL/min
per 1.73 m2 or albuminuria 30 mg/g, (versus no CKD) was 1.54 (95% confidence interval, 1.15–2.06). Associations were
consistent in subgroups according to age, sex, and comorbidities, and for unprovoked versus provoked VTE, as well.
Conclusions—Both eGFR and ACR are independently associated with increased risk of VTE in the general population,
even across the normal eGFR and ACR ranges. (Circulation. 2012;126:1964-1971.)
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The overall incidence rate of venous thromboembolism(VTE) in developed countries is 1.5 per 1000 person-
years, varying from0.05 in children to nearly 10.0 per 1000
person-years in the older adults.1–4 The 28-day case-fatality
rate after a first VTE is as high as 11%.4 Because none of the
known VTE risk factors are present in up to 50% of VTE
cases,3 identifying novel risk factors for VTE is the focus of
intensive research.
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Nephrotic syndrome and overt proteinuria are well-known
risk factors for VTE.5,6 Mild to moderate chronic kidney
disease (CKD) is associated with a procoagulant profile7–12
and might therefore also be related to VTE risk. Two recent
studies suggested that CKD may be associated with increased
VTE risk, with some conflicting results.13–15 Of the 2 key
CKD-defining kidney measures (ie, glomerular filtration rate
[GFR] and albuminuria), in the Atherosclerosis Risks in
Communities (ARIC) study, a significant association was
found only between reduced GFR and VTE incidence,14
whereas, in the Prevention of Renal and Vascular End-stage
Disease (PREVEND) study, an association was observed
only for elevated albuminuria.13 Possible explanations for
these inconsistent findings might be the limited statistical
power of the individual studies and differences in study
population characteristics or the selection of covariates.
Given the high prevalence of CKD (10%–16%) in the
general adult population,16–19 in-depth analysis of the asso-
ciation of CKD with VTE incidence is warranted. Hence, we
conducted an individual-level meta-analysis of 5 prospective
general population–based cohorts with information on GFR,
albuminuria, and incident VTE. This report explores the
separate and combined associations of GFR and albuminuria
with the risk of VTE.
Methods
Study Selection Criteria
To select eligible studies, we used criteria similar to those of the
CKD Prognosis Consortium20,21; eligible studies had to be
community-based cohort studies with both baseline estimated glo-
merular filtration rate (eGFR) and urine albumin measurements. A
PubMed search was performed on March 2, 2010 with the use of the
following combination of terms: (eGFR OR GFR OR “glomerular
filtration rate” OR “kidney function” OR “renal function” OR
“microalbuminuria” OR albuminuria OR “albumin to creatinine
ratio” OR ACR OR “urinary albumin concentration” OR UAC)
AND (“venous thrombosis” OR “venous thromboembolism” OR
“pulmonary embolism” OR “deep vein thrombosis” OR DVT) AND
(adult [MeSH]) AND (humans [MeSH]). Two investigators (B.K.M.
and R.T.G.) performed the search independently. No language or
publication period restrictions were applied. Subsequently, we
searched general population studies, with albumin-to-creatinine ratio
(ACR) ascertainment, that participated in the CKD Prognosis Con-
sortium21 in PubMed for availability of VTE outcomes. Finally,
additional eligible cohorts were sought during scientific meetings
and via personal contacts. The ethical review committee of the
University Medical Center of Groningen approved the project to
receive and analyze the data. Review committees of each participat-
ing cohort approved sharing of the deidentified individual-level data
and the conducted analyses presented in this article.
Baseline Study Variables
GFR was estimated with the use of the CKD Epidemiology Collab-
oration equation that takes into account serum creatinine, age, sex,
and race.22 In 3 studies, serum creatinine was not standardized to
isotope dilution mass spectrometry, hence we reduced the creatinine
levels by 5%, the calibration factor used to adjust nonstandardized
Modification of Diet in Renal Disease Study samples to isotope
dilution mass spectrometry.23 In a sensitivity analysis, GFR was
estimated by the use of the Modification of Diet in Renal Disease
equation.24 Albuminuria was quantified by the ratio of urinary
albumin to urinary creatinine excretion in a spot or 24-hour urine
sample.25,26 CKD was defined as eGFR 60 mL/min per 1.73 m2 or
ACR 30 mg/g, according to prevailing guidelines.25 History of
cardiovascular disease was defined as history of self-reported myo-
cardial infarction or stroke at study baseline. Hypertension was
defined as systolic blood pressure 140 mm Hg, diastolic blood
pressure 90 mm Hg, or the use of antihypertensive medication.
Diabetes mellitus was defined as a fasting glucose concentration of
7.0 mmol/L (126 mg/dL), a nonfasting glucose concentration of
11.1 mmol/L (200 mg/dL), or the use of glucose-lowering drugs
or self-reported diabetes mellitus. Smoking was dichotomized to
current smokers versus former or nonsmokers. Hypercholesterolemia
was defined as a total cholesterol concentration of 5.0 mmol/L
(193 mg/dL) in patients with a history of myocardial infarction or
stroke and as6.0 mmol/L (232 mg/dL) in patients without a history
of myocardial infarction and stroke. Body mass index (BMI) was
calculated as measured body weight in kilograms divided by height
in meters squared.
Venous Thromboembolism
Only objectively verified symptomatic VTEs were considered in all
cohorts. Deep vein thrombosis was confirmed by compression
ultrasound or venography, and pulmonary embolism was confirmed
by ventilation/perfusion lung scanning, angiography, spiral com-
puted tomography, or at autopsy. Major trauma, surgery, significant
immobilization, or active cancer in the proceeding 3 months were the
main determinants for classifying VTE as provoked.4,13,27,28 Three of
the 5 cohorts included additional risk factors in the definitions of
provoked VTE, such as the use of oral contraceptives or hormone
therapy, pregnancy, long-distance travel, active infectious disease,
acute myocardial infarction, paresis/paralysis of the leg, and heart
failure.13,27,28 In the absence of the aforementioned risk factors, VTE
was classified as unprovoked.
Statistical Analysis
Individual participant data from the cohorts were pooled. Cox
proportional hazards models with shared frailty (ie, random effects)
were used to estimate adjusted hazard ratios (HRs) of VTE associ-
ated with eGFR, albuminuria, and their combination. Individual
cohort was considered as the shared frailty variable to account for
between-study differences. As sensitivity analysis, continuous eGFR
and ACR associations with VTE were also modeled by using
stratified (ie, fixed effects) Cox proportional hazards regression.
Based on previous literature on risk factors for VTE and correlates
of eGFR and ACR, age, sex, BMI, history of cardiovascular disease,
hypertension, diabetes mellitus, total cholesterol, and current smok-
ing were included in models as potential confounders.13,14,29 Because
only 2 of the 5 studies also enrolled black participants, ethnicity-
specific results were presented for those 2 studies rather than
including race as a covariate in the main model. In addition, all eGFR
models were adjusted for log-ACR, and all ACR models were
adjusted for eGFR splines. To assess the shape of the relationship of
eGFR and ACR with the risk of VTE, we modeled eGFR and ACR
by using linear splines with knots at 45, 60, 75, 90, and 105 mL/min
per 1.73 m2 for eGFR, and 10, 30, 300, and 1000 mg/g (to convert
to milligrams per millimole, multiply by 0.113) for ACR, respec-
tively. eGFR of 100 mL/min per 1.73 m2 and ACR of 5 mg/g were
selected as reference points. HRs of eGFR association with VTE
were estimated per 1 mL/min per 1.73 m2 increment of eGFR from
15 to 120 mL/min per 1.73 m2. HRs for the association of ACR with
VTE were estimated per 8% increments of ACR from 2.5 to 1000
mg/g. Adjustment for prevalent baseline traditional VTE risk factors
(ie, major trauma, surgery, significant immobilization, or active
cancer) was not performed because these were not uniformly
available; however, given the temporary nature of these risk factors,
baseline prevalence of these risk factors is unlikely to influence
long-term VTE risk. To quantify short-term influence of these risk
factors on the association of eGFR and albuminuria with VTE, we
performed stratified analysis for provoked versus unprovoked VTE,
where the definition of provoked VTE incorporated the presence of
the traditional VTE risk factors.
Joint effects of eGFR and ACR on VTE were investigated by
using cross-tabulation of eGFR and ACR categories. The interaction
between eGFR and ACR was assessed by likelihood ratio tests
between the models with eGFR and measured ACR with and without
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their product terms. This methodology was also used to assess
interactions of CKD with sex, race, age, hypertension, diabetes
mellitus, smoking, hypercholesterolemia, history of cardiovascular
disease, and BMI. Moreover, for dichotomous CKD VTE risk
association, pooled estimates of the HRs and 95% confidence
intervals (CIs) of individual studies were obtained from random-
effects meta-analysis. Heterogeneity among studies was estimated by
2 test and the I2 statistics.30 Potential sources of heterogeneity were
explored by meta-regression analysis.
Because ACR was measured in only a subset of the second
Nord-Trøndelag Health Study (HUNT2) cohort, we adjusted the
eGFR-VTE associations for log-ACR values based on multiple
imputation.31 To achieve maximum accuracy for the imputed log-
ACR, we created 20 complete data sets by the use of Stata ice
command, which based the imputations on linear regression with
bootstrap estimation method.31,32 Subsequently the micombine com-
mand with Cox regression was used to obtain HRs and correct 95%
CIs. Age, sex, hypertension, diabetes mellitus, a history of cardio-
vascular disease, VTE and log-transformed follow-up time were
used to impute log-ACR values. To avoid potential bias due to
multiple imputation, analyses of the ACR-VTE risk association were
based on measured ACR values only. Statistical significance was
considered as a 2-tailed P0.05. All statistical analyses were
performed by the use of Stata software version 11.2 (StataCorp LP).
Results
Figure 1 shows the flow diagram of the identified studies.
Investigators of one of the eligible studies could not provide
data.33 Characteristics of the included studies are presented in
Table 1. Overall, 95 154 participants (46.7% males, 96.6%
whites) were included with 599 453 person-years of follow-
up. During follow-up, 1178 VTEs occurred, 45% were
classified as unprovoked, and 39% were pulmonary embo-
lism alone or in combination with deep vein thrombosis. In all
cohorts combined, 94 882 (99.7%) participants had measured
eGFR data and 39 524 (41.5%) had ACR data (in HUNT2
only, 15% of participants had ACR measured; n9737). All
other variables presented in Table 1 had 0.8% missing
values in the pooled data set, with the exception of current
smoking (4.4% missing).
199 Citaons idenﬁed through PubMed search
3 general populaon cohorts idenﬁed with
informaon on eGFR, albuminuria and VTE13,14*
197 excluded aer tle and abstract
screen (did not fulﬁll inclusion criteria)
1 addional cohort28 idenﬁed from 
screening of 14 general populaon 
cohorts from CKD Prognosis Consorum21
2 addional cohorts27,33 idenﬁed via 
personal contacts and scienﬁc meengs
1 cohort unable to provide data33
5 cohorts included in the analysis
Figure 1. Flow diagram for selection of studies. *Reference 14
included analysis of 2 cohorts. eGFR indicates estimated glo-
merular filtration rate; VTE, venous thromboembolism; and CKD,
chronic kidney disease.













Participants, n 11 513 3450 64 793 8573 6825
Male, % 44.1 39.7 46.9 50.0 49.2
Mean age, y 62.8 78.1 50.2 49.0 60.2
Black, % 22.5 16.6 0.0 1.0 0.0
Hypertension, % 47.7 72.5 45.1 34.1 50.2
Diabetes, % 16.8 22.2 3.0 4.4 3.4
Hypercholesterolemia, % 21.2 27.3 46.6 37.9 70.8
Current smoking, % 14.8 7.6 29.8 34.2 31.8
History of MI or stroke, % 10.1 16.5 4.9 4.5 8.5
Mean body mass index, kg/m2 28.8 26.9 26.3† 26.1 26.0
Mean total cholesterol, mg/dL 200 203 228 218 259
Mean eGFR, mL/min per 1.73 m2 84.3 67.6 97.9 88.8 92.8
Median ACR, mg/g 3.7 10.2 7.7 7.0 5.4
Mean follow-up, y 8.0 4.5 5.2 9.3 10.8
Venous thromboembolism, n 260 61 509 122 226
eGFR was estimated by the CKD-EPI equation.22 To convert total cholesterol to millimoles per liter,
multiply by 0.0259. To convert ACR to milligrams per millimole, multiply by 0.113. MI indicates
myocardial infarction; ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate;
CKD, chronic kidney disease; CKD-EPI, CKD Epidemiology Collaboration; and BMI, body mass index.
*Because albuminuria was measured at visit 4 in ARIC and the year 7 in CHS, we treated these
visits as the baseline for ARIC and CHS.
†In subjects with measured ACR in the HUNT2 study, mean BMI was 28 kg/m2 as depicted in
online-only Data Supplement Figure IV.
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Estimates of adjusted HRs for VTE according to eGFR and
ACR levels are presented in Figure 2. Risk of VTE started to
be significantly increased at eGFR 88 mL/min per 1.73 m2.
Relative to eGFR 100 mL/min per 1.73 m2, HRs for VTE
were 1.29 (95% CI, 1.04–1.59) for eGFR 75, 1.31 (1.00–
1.71) for 60, 1.82 (1.27–2.60) for 45, and 1.95 (1.26–3.01)
for 30 mL/min per 1.73 m2. Similar findings were observed in
analyses with the use of the Modification of Diet in Renal
Disease equation-based eGFR (online-only Data Supplement
Figure I). The interpretation of results did not change in
models comparing ACR as a covariate with and without the
use of imputed ACR from the HUNT2 study, indicating the
validity of the multiple imputation (online-only Data Supple-
ment Figure II). The association of ACR splines and VTE risk
was largely linear on the log-log scale, with significantly
increased risk observed at ACR 14 mg/g and higher. In
comparison with an ACR of 5.0 mg/g, the HRs for VTE were
1.34 (1.04–1.72) for 30 mg/g, 1.60 (1.08–2.36) for 300 mg/g,
and 1.92 (1.19–3.09) for 1000 mg/g (Figure 2B). Results of
fixed-effect Cox proportional hazards models were identical
to the random-effect models (online-only Data Supplement
Figure III).
Table 2 shows the adjusted HR of VTE in clinical
categories of eGFR and ACR based on Kidney Disease
Outcomes Quality Initiative (K/DOQI) staging.25 The corre-
sponding number of VTEs and total number of participants
according to these categories are presented in online-only
Data Supplement Table I. In general, the association of ACR
with VTE risk was evident across most eGFR categories. The
association between reduced eGFR and VTE risk was more
obvious in those with normoalbuminuria (ie, ACR 30
mg/g). The risk increase was not clearly multiplicative with
lower eGFR and higher ACR categories; tests for interaction
of the separate categories (P0.14) and overall (P0.20)
were not significant. The interaction of continuous eGFR
with spline terms and linear log-ACR was not significant
(P0.10).
When we compared individuals with CKD versus no-CKD,
the pooled HR for overall VTE associated with CKD was
1.54 (95% CI, 1.15–2.06) (Figure 3). In Figure 4, the impact
of CKD on overall VTE incidence was consistent across the
subgroups tested, with the exception of a trend for BMI
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Figure 2. Pooled hazard ratios and 95% CIs for venous thromboembolism according to spline estimated glomerular filtration rate
(eGFR) and albumin-to-creatinine ratio (ACR). Hazard ratios and 95% confidence intervals (error bars) according to eGFR (A) and ACR
(B) adjusted for each other, age, sex, body mass index, history of cardiovascular disease, hypertension, diabetes mellitus, smoking,
and total cholesterol. The reference (diamond) was eGFR 100 mL/min per 1.73 m2 and ACR 5 mg/g (0.6 mg/mmol), respectively. Black
dots represent statistical significance. To convert ACR to milligrams per millimoles multiply by 0.113. Num Part and Num VTE indicate
the number of participants and number of VTE, respectively, in the range between the knots represented by the vertical gray lines; CI,
confidence interval; and VTE, venous thromboembolism.
Table 2. Pooled Estimates of Adjusted Hazard Ratios (95%
Confidence Intervals) for Venous Thromboembolism According












Reference 1.66 (1.11–2.48) 1.51 (0.48–4.73)
60–89 mL/min
per 1.73 m2
1.15 (0.96–1.38) 1.47 (1.07–2.03) 4.38 (2.64–7.26)
45–59 mL/min
per 1.73 m2
1.23 (0.87–1.74) 1.37 (0.76–2.49) 1.51 (0.48–4.77)
30–44 mL/min
per 1.73 m2
2.13 (1.26–3.62) 2.11 (0.95–4.95) 2.33 (0.74–7.34)
From the HUNT2 study, only subjects with measured ACR contributed to this
analysis. eGFR was estimated by the CKD-EPI equation.22 Given the low
numbers of individuals with eGFR30 (see online-only Data Supplement Table
I), these individuals were excluded from this analysis. eGFR indicates estimated
glomerular filtration rate; ACR, albumin-to-creatinine ratio; CKD, chronic kidney
disease; and CKD-EPI, CKD Epidemiology Collaboration.
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subjects with BMI 25 versus 25 kg/m2 (P for interac-
tion0.06). Similarly, the significant heterogeneity observed
for overall VTE among studies appeared to be due to
differences in BMI across studies (0.23, P0.054)
(online-only Data Supplement Figure IV).
The HRs of VTE with CKD in comparison with no CKD
were similar for unprovoked and provoked VTE (Figure 3).
Analyses for continuous eGFR and ACR are presented in the
online-only Data Supplement Figure V. Similarly, the HRs of
pulmonary embolism and deep vein thrombosis with CKD
were similar (online-only Data Supplement Figure VI). Fi-
nally, of the covariates, only BMI and age showed significant
strong association with VTE in all models of eGFR and ACR
(data not shown).
Discussion
In this individual participant meta-analysis including 95 154
participants from prospective observational studies followed
for an average of 6.3 years, both eGFR and elevated albu-
minuria were associated with increased risk of VTE indepen-
dently of each other and traditional cardiovascular risk factors
including BMI. For both eGFR and ACR, there was a
dose–response relationship with increased risk of VTE start-
ing in the non-CKD range of eGFR (ie, 60 mL/min per 1.73
m2) and the normal range of ACR (ie, 30 mg/g). There was
no significant interaction between eGFR and ACR. CKD,
defined by eGFR 60 mL/min per 1.73 m2 or ACR 30
mg/g, was similarly associated with both provoked and
unprovoked VTE and with both pulmonary embolism and
deep-vein thrombosis.
In this comprehensive analysis of large prospective general
population–based cohorts, a clear association of eGFR and
albuminuria with risk of VTE clarifies the previous inconsis-
tent published findings of the ARIC and PREVEND studies.
In addition to ARIC and PREVEND cohorts, this analysis
included previously unpublished data from 3 additional co-
horts. The association of CKD with VTE was largely consis-
tent in the presence versus the absence of various traditional
cardiovascular risk factors, with the exception of a trend for
relatively stronger association of CKD with VTE in subjects
with BMI 25 kg/m2 in comparison with BMI 25 kg/m2
(P0.06). Difference in mean BMI among studies also
explained most of the variability of the CKD-VTE risk
association across studies. This finding is in line with several
observational studies that reported an antagonistic interaction
between BMI and CKD on mortality.34
The observation that risks do not fully multiply when both
eGFR is low and ACR is high might be secondary to
competing risk for mortality in low eGFR and high ACR
categories, and to limited power in the low-eGFR and
high-albuminuria categories, as well (online-only Data Sup-
plement Table I). However, a significant interaction between
eGFR and ACR categories in relation to mortality was not
observed in a recent meta-analysis.21
CKD is associated with a broad range of diseases requiring
hospitalization. This may have resulted in the association
between CKD and provoked VTE. However, the association
of eGFR and albuminuria with unprovoked VTE gives
credence to a direct association of CKD with VTE. The high
risk of VTE in individuals diagnosed with nephrotic-range
proteinuria is assumed to be secondary to the loss of antico-
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Figure 3. Overall and study-specific haz-
ard ratios for overall, unprovoked, and
provoked venous thromboembolism in
participants with CKD in comparison
with those without CKD. CKD was
defined by eGFR of 60 mL/min per
1.73 m2 and/or ACR 30 mg/g.25 Hazard
ratios are adjusted for age, sex, body
mass index, history of cardiovascular
disease, hypertension, diabetes mellitus,
smoking, and total cholesterol. The slight
differences in numbers with Table 1 are
due to missing observations for either
eGFR or ACR, and because, for defining
non-CKD, both eGFR and ACR were
required. For the HUNT2 study only,
measured ACR was considered in this
analysis. eGFR indicates estimated glo-
merular filtration rate; ACR, albumin-to-
creatinine ratio; VTE, venous thrombo-
embolism; and CKD, chronic kidney
disease; and CI, confidence interval.
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agulant proteins.6 The increased risk of VTE with mild to
moderate CKD may be secondary to endothelial injury and
the related changes in procoagulant proteins such as increased
levels of fibrinogen, factor VII, factor VIII, von Willebrand
factor, and plasminogen activator inhibitor-1 or increased
levels of D-dimers.7–12 An increased procoagulant state in
CKD patients was also confirmed by functional coagulation
assays such as prothrombin fragment 12, thrombin–anti-
thrombin complex, plasmin–antiplasmin complex, and in
vitro thrombin generation assessed by a calibrated automated
thrombogram, as well.7,8,10,35 The well-known link of CKD
with arterial cardiovascular disease and mortality36 is also
assumed to be at least partially due to a hypercoagulable
state.7,8,10
The high prevalence of CKD in the general population
(10%–16%) suggests that, on the population level,16–19 CKD
may explain a much larger proportion of VTE risk than most
of the established rare hereditary VTE risk factors, such as
antithrombin, protein C, and protein S deficiencies.37 Assum-
ing a CKD prevalence of 10% in the general population, the
observed HR of 1.54 in our study corresponds to a
population-attributable risk of 5.1%, if the relationship is
causal. In contrast to most established VTE risk factors,
CKD, in particular, albuminuria, is modifiable with medica-
tions (eg, renin-angiotensin system inhibitors).38,39 In fact,
losartan use in patients with overt proteinuria 2.0 g/d
ameliorates the hypercoagulable state in proteinuric pa-
tients.35 Taken together with our findings, studies evaluating
the effect of albuminuria-lowering drugs on the risk of VTE
in patients with mild to moderate CKD are warranted.
Furthermore, because CKD is common, based on the current
findings, it would be useful to assess whether CKD might be
associated with the risk of recurrent VTE.
We acknowledge that this study has limitations. First, the
measurement of creatinine, albuminuria, and potential con-
founders was not standardized among all studies. For in-
stance, some studies measured albumin and creatinine in
fresh urine samples, whereas other studies used frozen sam-
ples, and there was no centralized laboratory for all studies
together. Care was taken, however, to use the same defini-
tions for exposure variables and covariates across studies.
Second, whereas we accounted for cardiovascular risk factors
as potential confounders that are strongly associated with
CKD and possibly associated with VTE, residual confound-
ing may still remain. Although we were not able to account
for hereditary thrombophilic defects, these are not known to
be associated with mild to moderate CKD. In fact, 1 recent
study reported a renoprotective effect of factor V Leiden.40
Third, event ascertainment across studies was comparable,
but the definitions of unprovoked and provoked VTE were
slightly different. However, we observed largely consistent
findings for the association of CKD with overall, unpro-
voked, and provoked VTE. Fourth, we are unable to account
for anticoagulant medication use. However, given that CKD
is associated with cardiovascular disease, ignoring anticoag-
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Figure 4. Association of CKD with VTE in subgroups according to traditional cardiovascular risk factors. CKD was defined by eGFR of
60 mL/min per 1.73 m2 or ACR 30 mg/g.25 Hazard ratios are adjusted for other than the stratified risk factor itself, which included
age, sex, body mass index, history of cardiovascular disease, hypertension, diabetes mellitus, smoking, and total cholesterol. *Race
comparison was limited to ARIC and CHS studies, because the other studies enrolled only whites. CVD indicates cardiovascular dis-
ease; eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine ratio; VTE, venous thromboembolism; and CKD, chronic
kidney disease; HR, hazard ratio; CI, confidence interval; and BMI, body mass index.
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CKD-VTE risk association. Last, meta-regression analysis
that explored the variation of HRs across studies was under-
powered given the small number of studies in current analy-
sis. Nevertheless, the association of BMI with the variation of
HRs of the association of CKD with VTE risk reached
borderline significance, suggesting that the heterogeneity
across studies might be secondary to differences in mean
BMI.
In conclusion, both eGFR and ACR are independently
associated with increased risk of VTE in the general popula-
tion, even in the non-CKD range of eGFR and the normal
range of ACR.
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CLINICAL PERSPECTIVE
Chronic kidney disease (CKD) is a major health problem that affects 10% to 16% of the general adult population. Whereas
associations of CKD with arterial thromboembolism and mortality are well known, the association of CKD with venous
thromboembolism (VTE) is uncertain. In the present study, we assessed the association of CKD with venous thrombosis
in 5 general population cohorts. The key CKD measures (ie, decreased estimated glomerular filtration rate and elevated
albumin-to-creatinine ratio) were both associated with an increased risk of VTE, even for values in the normal ranges.
Subjects with CKD (ie, estimated glomerular filtration rate 60 mL/min per 1.73 m2 or albumin-to-creatinine ratio 30
mg/g) had a 54% higher risk of VTE in comparison with subjects without CKD. The associations were similar for
unprovoked and provoked VTE, and for pulmonary embolism and deep-vein thrombosis, as well. CKD measures showed
largely similar associations with VTE across subgroups of traditional cardiovascular risk factors, such as hypertension,
diabetes, age, and sex. Given the effect size of the association, individual-level implications may be limited. Nevertheless,
because of the high prevalence of CKD, population-level VTE burden owing to CKD is estimated to be high, especially
in populations with high CKD prevalence such as those with diabetes mellitus and hypertension. Future studies are
warranted to assess whether CKD is also associated with recurrent VTE. If confirmed, these findings may have
implications for the duration of anticoagulant treatment for first VTE.
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